Who are Veradermics's main competitors?

Named competitors: Hims & Hers Health (HIMS), Cosmo Pharmaceuticals (private or unlisted). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Abbott India (ABBOTINDIA.NS), Apotex Health (APTX.TO), Gland Pharma (GLAND.NS), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND).

How has Veradermics stock performed?

Over six months to 6 Nov 2026 the shares returned +30.8% against -5.2% for the median peer.

← CockpitCompetitor Analysis › MANE Veradermics, IncorporatedOpen in the cockpit ↗

Veradermics, IncorporatedMANECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.

Momentum leader 91

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$5.80B

US dollars, full cap

Free float

71%

of shares outstanding

$/day

$86.3M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 10.2%

Hurdle

n/a

no reverse DCF

Next earnings

26 days

2 Dec 2026

Close · USD$138.78

1D+7.9%

1W-0.7%

1M+9.6%

3M+25.3%

6M+30.8%

YTDn/a

1Yn/a

ATR %6.2%

52w lowhigh5.3% off high

What Veradermics does

Dermatology-focused pharmaceutical company; specific pipeline and commercial products not confidently known from public knowledge.

Where it sits in the supply chain

Pharmaceuticals
Dermatology

Moat: none

Employees: 21

Named competitors

Hims & Hers Health HIMS
Cosmo Pharmaceuticals private or unlisted

Veradermics at a glance

Size Veradermics (MANE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.80B, the 1085th largest of 3,117 United States companies the cockpit tracks. Shares closed at $138.78 on 6 Nov 2026.

Performance Over six months the shares gained 30.8%, against -5.2% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Short interest Short interest is 8.8% of the free float (15 Oct 2026).

Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Veradermics against the median of its 20 peers (local-currency closes).

Veradermics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023
Revenue	n/a	$0	$0	$0
Revenue growth	—	—	—	—
Gross profit	n/a	$0	$0	$0
EBITDA	n/a	-$72.3M	-$26.8M	-$17.3M
Net income	n/a	-$70.0M	-$26.5M	-$16.5M
Free cash flow	n/a	-$71.6M	-$23.7M	-$13.5M
Capital expenditure	n/a	$24,000	$0	$0
Total debt	$428,000	$4,000	$0	$786,000

Quarterly statements and history in the cockpit →

Veradermics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Veradermics is the large dot.

Veradermics competitors and peer comparison

Head to head with its named competitors (MANE vs HIMS)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
Veradermics MANE	$5.80B	+31%	n/a	n/a	n/a	n/a
Hims & Hers Health HIMS	$6.07B	-8%	+28%	0%	2.6×	54.9%

How Veradermics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Veradermics against its 20 peers (data as of 6 Nov 2026)
Measure	MANE	Peer median	Rank in peer set
1-month return	+9.6%	+1.3%	4th highest of 21
6-month return	+30.8%	-5.2%	3rd highest of 20
Distance from 52-week high	-5.3%	-25.4%	3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Veradermics MANE	United States	$5.80B	+31%	n/a	n/a	n/a	n/a	n/a
Shanghai Allist Pharmaceuticals 688578.SS	China	$5.90B	-6%	+39%	47%	5.4×	1.8%	+519.6%
Abbott India ABBOTINDIA.NS	India	$5.93B	-1%	+6%	28%	8.0×	11.4%	+10.0%
Apotex Health APTX.TO	Canada	$5.62B	n/a	+4%	32%	3.0×	-13.5%	+4.2%
Gland Pharma GLAND.NS	India	$5.53B	+69%	+18%	20%	7.8×	28.0%	+13.3%
Mirum Pharmaceuticals MIRM	United States	$6.12B	-13%	+42%	-21%	9.7×	n/a	n/a
Ligand Pharmaceuticals LGND	United States	$6.12B	+38%	+1%	14%	26.9×	57.8%	+7.5%
PTC Therapeutics PTCT	United States	$5.47B	-11%	-35%	22%	3.4×	8.0%	+35.4%
Supernus Pharmaceuticals SUPN	United States	$5.43B	-49%	+16%	45%	4.1×	4.2%	+13.9%
Belite Bio, Inc. ADR BLTE	United States	$6.20B	0%	n/a	n/a	n/a	n/a	n/a
Biocon BIOCON.NS	India	$6.28B	-4%	+6%	8%	4.3×	n/a	n/a
Beijing TongRenTang 600085.SS	China	$5.27B	-8%	-17%	8%	2.4×	2.7%	+6.2%
Samsung Epis 0126Z0.KS	South Korea	$6.39B	-36%	n/a	-25%	34.5×	n/a	n/a
Gan & Lee Pharmaceuticals 603087.SS	China	$6.40B	+21%	+14%	20%	8.8×	n/a	n/a
Sumitomo Pharma 4506.T	Japan	$5.23B	+7%	+11%	10%	1.8×	1.4%	-2.6%
IPCA Laboratories IPCALAB.NS	India	$5.22B	+24%	+11%	17%	4.9×	17.8%	+12.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ	China	$6.48B	0%	+4%	14%	1.9×	-6.3%	+18.4%
Shenzhen Salubris Pharmaceuticals 002294.SZ	China	$5.18B	-39%	+14%	11%	7.0×	15.5%	+9.7%
Ionis Pharmaceuticals IONS	United States	$6.55B	-48%	-7%	-68%	7.7×	n/a	n/a
SKBP 326030.KS	South Korea	$5.12B	-11%	+39%	35%	8.1×	0.5%	+93.6%
Alkem Laboratories ALKEM.NS	India	$6.67B	-5%	+13%	17%	4.2×	24.3%	+10.7%

Questions

Who are Veradermics's main competitors?: Named competitors: Hims & Hers Health (HIMS), Cosmo Pharmaceuticals (private or unlisted). The cockpit's measured peer set (industry) also includes Shanghai Allist Pharmaceuticals (688578.SS), Abbott India (ABBOTINDIA.NS), Apotex Health (APTX.TO), Gland Pharma (GLAND.NS), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND).
How has Veradermics stock performed?: Over six months to 6 Nov 2026 the shares returned +30.8% against -5.2% for the median peer.